Clinical trial NCT00006451 (phase 3, status: withdrawn)
Conditions: graft versus host disease, leukemia, lymphoma
ICD codes: D89.810, D89.811, D89.813, D89.812, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: anti-thymocyte globulin, cyclophosphamide, cyclosporine, methotrexate, methylprednisolone
SMILES: COC1=CC=CC=C1OCC(O)CO, ClCCN(CCCl)P1(=O)NCCCO1, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Reason stopped: 
    terminated (due to no accrual)
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Acute myelocytic leukemia with or without history of
        myelodysplastic syndrome Not in first complete remission (i.e., greater than 5% blasts in
        marrow) with t(8;21), t(15;17), or 16q abnormality unless failure on first-line induction
        therapy Acute lymphocytic leukemia (ALL) in one of the following categories: In second or
        third complete remission (CR) High-risk ALL in first CR, with high risk defined as:
        Hypodiploidy OR pseudodiploidy with t(9;22), t(4;11), or t(8;14) Failure to achieve CR
        after 4 weeks of induction therapy Elevated WBC at presentation, i.e.: Greater than 100,000
        in patients aged 6 to 12 months Greater than 200,000 in patients aged 1 to 20 years Greater
        than 20,000 in patients aged 21 to 44 years Chronic myelogenous leukemia not in blast
        crisis (i.e., no greater than 30% promyelocytes plus blasts in bone marrow) Stage IV
        lymphoblastic lymphoma Undifferentiated or biphenotypic leukemia Unrelated donor available
        Patients aged 35 and younger: HLA-A, and -B serologic identity and HLA-DRB1 identity by
        high-resolution DNA typing OR Single HLA-A or -B serologic mismatch with DRB1 identity by
        high-resolution DNA typing OR HLA-A and -B serologic identity with single DRB1 mismatch by
        high- or low- resolution DNA typing Patients aged 36 to 44: HLA-A and -B serologic identity
        and HLA-DRB1 identity by high-resolution DNA typing The following exclude: Relapse 12
        months after discontinuing therapy in patients aged 1 to 10 years who are in second
        remission Active central nervous system or leukemic skin involvement Requirement for
        additional mediastinal irradiation

        PATIENT CHARACTERISTICS: Age: Under 46 Performance status: Karnofsky 70-100% Lansky 50-100%
        Hematopoietic: See Disease Characteristics Hepatic: Bilirubin less than 2.5 mg/dL AST less
        than 3 times normal Renal: Creatinine normal OR Creatinine clearance greater than 60 mL/min
        Cardiovascular: Asymptomatic OR Resting LVEF greater than 40% and improves with exercise
        Pulmonary: Asymptomatic OR DLCO greater than 45% of predicted (corrected for hemoglobin)
        Other: HIV negative No uncontrolled viral, bacterial, or fungal infection Not pregnant or
        nursing

        PRIOR CONCURRENT THERAPY: No prior bone marrow transplantation No prior radiotherapy that
        precludes total body irradiation